Anti-tumour effect of tocilizumab for osteosarcoma cell lines

AIMS: Tocilizumab, an interleukin-6 (IL-6) receptor (IL-6R) targeting antibody, enhances the anti-tumour effect of conventional chemotherapy in preclinical models of cancer. We investigated the anti-tumour effect of tocilizumab in osteosarcoma (OS) cell lines. METHODS: We used the 143B, HOS, and Sao...

Descripción completa

Detalles Bibliográficos
Autores principales: Hagi, Tomohito, Nakamura, Tomoki, Kita, Kouji, Iino, Takahiro, Asanuma, Kunihiro, Sudo, Akihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The British Editorial Society of Bone & Joint Surgery 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672325/
https://www.ncbi.nlm.nih.gov/pubmed/33179539
http://dx.doi.org/10.1302/2046-3758.911.BJR-2020-0123.R1
_version_ 1783611109451759616
author Hagi, Tomohito
Nakamura, Tomoki
Kita, Kouji
Iino, Takahiro
Asanuma, Kunihiro
Sudo, Akihiro
author_facet Hagi, Tomohito
Nakamura, Tomoki
Kita, Kouji
Iino, Takahiro
Asanuma, Kunihiro
Sudo, Akihiro
author_sort Hagi, Tomohito
collection PubMed
description AIMS: Tocilizumab, an interleukin-6 (IL-6) receptor (IL-6R) targeting antibody, enhances the anti-tumour effect of conventional chemotherapy in preclinical models of cancer. We investigated the anti-tumour effect of tocilizumab in osteosarcoma (OS) cell lines. METHODS: We used the 143B, HOS, and Saos-2 human OS cell lines. We first analyzed the IL-6 gene expression and IL-6Rα protein expression in OS cells using reverse transcription real time quantitative-polymerase chain reaction (RT-qPCR) analysis and western blotting, respectively. We also assessed the effect of tocilizumab on OS cells using proliferation and invasion assay. RESULTS: The OS cell lines 143B, HOS, and Saos-2 expressed IL-6R. Recombinant human IL-6 treatment increased proliferation of 143B and HOS cells. Tocilizumab treatment decreased proliferation and invasion of 143B, HOS, and Saos-2. CONCLUSION: In conclusion, we confirmed the production of IL-6 and the expression of IL-6R in OS cells and demonstrated that tocilizumab inhibits proliferation and invasion in OS cells. Cite this article: Bone Joint Res 2020;9(11):821–826.
format Online
Article
Text
id pubmed-7672325
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The British Editorial Society of Bone & Joint Surgery
record_format MEDLINE/PubMed
spelling pubmed-76723252020-11-19 Anti-tumour effect of tocilizumab for osteosarcoma cell lines Hagi, Tomohito Nakamura, Tomoki Kita, Kouji Iino, Takahiro Asanuma, Kunihiro Sudo, Akihiro Bone Joint Res Oncology AIMS: Tocilizumab, an interleukin-6 (IL-6) receptor (IL-6R) targeting antibody, enhances the anti-tumour effect of conventional chemotherapy in preclinical models of cancer. We investigated the anti-tumour effect of tocilizumab in osteosarcoma (OS) cell lines. METHODS: We used the 143B, HOS, and Saos-2 human OS cell lines. We first analyzed the IL-6 gene expression and IL-6Rα protein expression in OS cells using reverse transcription real time quantitative-polymerase chain reaction (RT-qPCR) analysis and western blotting, respectively. We also assessed the effect of tocilizumab on OS cells using proliferation and invasion assay. RESULTS: The OS cell lines 143B, HOS, and Saos-2 expressed IL-6R. Recombinant human IL-6 treatment increased proliferation of 143B and HOS cells. Tocilizumab treatment decreased proliferation and invasion of 143B, HOS, and Saos-2. CONCLUSION: In conclusion, we confirmed the production of IL-6 and the expression of IL-6R in OS cells and demonstrated that tocilizumab inhibits proliferation and invasion in OS cells. Cite this article: Bone Joint Res 2020;9(11):821–826. The British Editorial Society of Bone & Joint Surgery 2020-11-12 /pmc/articles/PMC7672325/ /pubmed/33179539 http://dx.doi.org/10.1302/2046-3758.911.BJR-2020-0123.R1 Text en © 2020 Author(s) et al. https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND 4.0) licence, which permits the copying and redistribution of the work only, and provided the original author and source are credited. See https://creativecommons.org/licenses/by-nc-nd/4.0/.
spellingShingle Oncology
Hagi, Tomohito
Nakamura, Tomoki
Kita, Kouji
Iino, Takahiro
Asanuma, Kunihiro
Sudo, Akihiro
Anti-tumour effect of tocilizumab for osteosarcoma cell lines
title Anti-tumour effect of tocilizumab for osteosarcoma cell lines
title_full Anti-tumour effect of tocilizumab for osteosarcoma cell lines
title_fullStr Anti-tumour effect of tocilizumab for osteosarcoma cell lines
title_full_unstemmed Anti-tumour effect of tocilizumab for osteosarcoma cell lines
title_short Anti-tumour effect of tocilizumab for osteosarcoma cell lines
title_sort anti-tumour effect of tocilizumab for osteosarcoma cell lines
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672325/
https://www.ncbi.nlm.nih.gov/pubmed/33179539
http://dx.doi.org/10.1302/2046-3758.911.BJR-2020-0123.R1
work_keys_str_mv AT hagitomohito antitumoureffectoftocilizumabforosteosarcomacelllines
AT nakamuratomoki antitumoureffectoftocilizumabforosteosarcomacelllines
AT kitakouji antitumoureffectoftocilizumabforosteosarcomacelllines
AT iinotakahiro antitumoureffectoftocilizumabforosteosarcomacelllines
AT asanumakunihiro antitumoureffectoftocilizumabforosteosarcomacelllines
AT sudoakihiro antitumoureffectoftocilizumabforosteosarcomacelllines

Ejemplares similares